Related Experiment Videos
Do randomized controlled trials always trump case reports? A second look at propranolol and depression
Jennifer J G Steffensmeier1, Michael E Ernst, Michael Kelly
1Division of Clinical and Administrative Pharmacy, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, USA.
Pharmacotherapy
|February 10, 2006
Summary
Discrepancies exist between case reports and meta-analyses on beta-blockers and depression. Randomized controlled trials may not adequately assess depression as an adverse effect, suggesting case report evidence needs careful consideration.
Area of Science:
- Pharmacovigilance
- Clinical trial methodology
- Psychiatry
Background:
- Case reports suggest a link between beta-adrenergic blockers and depression.
- Meta-analyses of randomized controlled trials (RCTs) have not consistently supported this association.
- Discrepancies highlight potential issues in study design and data interpretation.
Purpose of the Study:
- To investigate the reasons for conflicting findings regarding beta-blockers and depression.
- To compare evidence from case reports with RCT meta-analyses.
- To identify methodological factors influencing the detection of depression as an adverse drug effect.
Main Methods:
- Systematic review of literature.
- Analysis of 24 case reports and 8 RCTs included in a meta-analysis.
- Evaluation of case report causality using Naranjo criteria.
- Assessment of depression assessment methods in RCTs.
Main Results:
- Twelve case reports (nine involving propranolol) suggested a likely association (Naranjo score ≥5).
- Depression onset was often shortly after treatment initiation in these cases.
- RCTs showed significant variability in depression rates (0-40%) and often lacked systematic depression assessment.
Conclusions:
- A definitive standard for assessing the beta-blocker-depression relationship is absent.
- RCTs may fail to detect depression due to inadequate assessment timing, methods, and patient selection.
- Case report findings warrant careful consideration, especially when RCTs have methodological limitations.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:54The Placebo Effect
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:52Regression Toward the Mean
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when researchers try to extrapolate results...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:11Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.